In January, just a few weeks after the passing of the 2018 Farm Bill, Applied Biosciences Corp. (OTC:APPB) added a major player from the pharmaceutical community to its team with the appointment of US Food and Drug Administration Science Advisor Dr. Xiang-Qun Xie to the company’s Scientific Advisory Board.
Now, just a few months later, Applied Biosciences has added yet another impressive member to its team with the appointment of Dr. Raymond W. Urbanski MD, PhD, the former business unit Chief Medical Officer and Senior Director of oncology research and development with Pfizer Inc. (NYSE:PFE), as its Chief Executive Officer.
According to the company’s press release, Dr. Urbanski brings “extensive experience in building highly effective and efficient organizations as well as experience in all phases of drug development” to Applied Biosciences, allowing the company to accelerate its cannabinoid-focused innovation initiatives.
“Since my days in practice I have been a believer in the cannabinoids. I always knew that the cannabinoids could be useful agents for the treatment of a whole range of ailments and diseases. As the science has progressed and some barriers have come down this is the ideal time and environment to make these products and drugs available. Applied BioSciences is uniquely poised to lead these efforts,“ commented Dr. Urbanski.
As Dr. Urbanski now takes over at the helm of Applied Biosciences, we’ll be looking to see how his big pharma industry touch impacts the company’s various business units ranging from testing and analytics to CBD brands and products.
In the meantime, be sure to subscribe to updates here so you never miss an important development.
Get Real-Time Updates from The Daily Marijuana Observer